A detailed history of Morgan Jess S & CO Inc transactions in Oramed Pharmaceuticals Inc. stock. As of the latest transaction made, Morgan Jess S & CO Inc holds 366,401 shares of ORMP stock, worth $828,066. This represents 2.07% of its overall portfolio holdings.

Number of Shares
366,401
Previous 315,301 16.21%
Holding current value
$828,066
Previous $1.44 Million 64.4%
% of portfolio
2.07%
Previous 1.5%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 21, 2022

BUY
$4.6 - $9.91 $235,059 - $506,401
51,100 Added 16.21%
366,401 $2.37 Million
Q2 2022

Jul 18, 2022

BUY
$3.72 - $9.0 $92,256 - $223,200
24,800 Added 8.54%
315,301 $1.44 Million
Q1 2022

May 16, 2022

BUY
$8.19 - $13.89 $615,069 - $1.04 Million
75,100 Added 34.87%
290,501 $2.51 Million
Q4 2021

Jan 27, 2022

BUY
$12.98 - $29.75 $2.8 Million - $6.41 Million
215,401 New
215,401 $3.08 Million
Q3 2021

Nov 09, 2021

SELL
$12.13 - $23.82 $3.91 Million - $7.68 Million
-322,249 Closed
0 $0
Q2 2021

Nov 30, 2021

SELL
$8.34 - $14.59 $481,176 - $841,770
-57,695 Reduced 15.19%
322,249 $4.31 Million
Q1 2021

Nov 30, 2021

SELL
$4.22 - $11.33 $832,914 - $2.24 Million
-197,373 Reduced 34.19%
379,944 $3.86 Million
Q4 2020

Nov 30, 2021

BUY
$2.48 - $4.64 $2,480 - $4,640
1,000 Added 0.17%
577,317 $2.45 Million
Q3 2020

Nov 29, 2021

BUY
$2.58 - $4.16 $421,633 - $679,843
163,424 Added 39.58%
576,317 $1.5 Million
Q2 2020

Nov 29, 2021

BUY
$2.87 - $4.12 $1.09 Million - $1.57 Million
380,993 Added 1194.34%
412,893 $1.46 Million
Q1 2020

Nov 29, 2021

BUY
$2.6 - $5.5 $2,600 - $5,500
1,000 Added 3.24%
31,900 $97,000
Q4 2019

Nov 19, 2021

BUY
$2.43 - $5.74 $75,087 - $177,366
30,900 New
30,900 $159,000

Others Institutions Holding ORMP

About ORAMED PHARMACEUTICALS INC.


  • Ticker ORMP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,827,100
  • Market Cap $87.7M
  • Description
  • Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...
More about ORMP
Track This Portfolio

Track Morgan Jess S & CO Inc Portfolio

Follow Morgan Jess S & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Jess S & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Jess S & CO Inc with notifications on news.